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Abstract 
For patients with acute myeloid leukemia (AML) early achievement of remission during 
induction treatment is an important predictor for long-term outcome irrespective of the type of 
consolidation therapy employed. Here, we retrospectively examined the prognostic impact of 
early remission (ER) versus delayed remission (DR) in a cohort of 132 AML patients with an 
intermediate risk karyotype undergoing allogeneic stem cell transplantation (alloSCT) in first 
complete remission (CR1). In contrast to patients showing DR, patients achieving ER had a 
significantly higher 3-year overall survival (OS) and disease-free survival (DFS) of 76% 
versus 54% (p=0.03) and 76% versus 53% (p=0.03). Likewise, three years after alloSCT the 
cumulative incidence of relapse (CI-R) was significantly lower in the ER subgroup as 
compared to patients achieving DR, i.e. 10% versus 35% (p=0.004), whereas non-relapse 
mortality (NRM) did not differ significantly. Multivariate analysis identified DR as an 
independent prognosticator for an inferior DFS (HR 3.37, p=0.002) and a higher CI-R (HR 
3.55, p=0.002). Taken together, these data may indicate that the rapid achievement of 
remission predicts a favorable outcome in patients with intermediate risk AML undergoing 
alloSCT in CR1. In turn, the adverse effect of DR may not be fully overcome by alloSCT.  
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Introduction 
AML is a highly heterogeneous disease and despite tremendous progress in understanding 
and treating this disorder has been made within the last decades, only a minor proportion of 
patients will be ultimately cured by conventional therapeutic approaches (1, 2). AlloSCT is 
the most effective treatment option for AML and, therefore, has become standard of care for 
the majority of medically fit patients with non-favorable risk disease if a human leukocyte 
antigen (HLA)-compatible donor is available (2-4). Nonetheless, as compared to conventional 
post-remission therapy, alloSCT is associated with a considerable risk of NRM, which may 
outweigh the potential survival advantage. 
In addition to patient-related variables such as comorbidities or physical performance, risk 
assessment in AML primarily includes pre-treatment disease-specific factors, e.g. genetic 
features, initial leukemic cell burden, preceding hematologic disorders such as 
myelodysplastic syndrome (MDS) or chronic myeloproliferative neoplasia (MPN), or a 
history of chemo- or radiation therapy. In addition, response to treatment was shown to 
predict outcome. As such, the rapid achievement of remission by induction therapy has long 
been recognized as a prognosticator for overall outcome (5-7). Likewise, early blast 
clearance, as determined one week after the first course of induction chemotherapy, predicts 
CR rate and has major prognostic relevance irrespective of the type of post-remission therapy 
(8-11). However, the impact of achieving early remission, i.e. absence of leukemic blasts in 
the bone marrow at the end of the first course of induction therapy, versus delayed remission 
on the outcome of patients with AML undergoing alloSCT has not yet been specifically 
explored. We therefore addressed this question in cohort of 132 consecutive patients with 
AML and an intermediate cytogenetic risk profile transplanted in CR1 at our center between 
1994 and 2013. 
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Patients and Methods 
Study design and data collection 
Base-line characteristics and post-transplant follow-up data of all patients were prospectively 
collected in a computer database. 132 consecutive patients with AML and an intermediate 
cytogenetic risk profile according to the definition of the Southwestern Oncology 
Group/Eastern Cooperative Oncology Group (SWOG/ECOG) (12) transplanted in CR1 at our 
center between 1994 and 2013 were retrospectively analyzed. All procedures were approved 
by the local ethics committee and are in full accordance with the Helsinki Declaration of 
1975. Informed consent was obtained from all patients. 
Patients and treatment characteristics 
Patients and treatment characteristics are detailed in Table 1. The entire cohort (N=132) was 
divided into patients who achieved ER (N=79) or DR (N=53). Before referral to our 
transplant center, all patients were treated in a German multicenter AML trial. All patients 
aged <60 years (N=113) were treated according to the double induction strategy (13). In this 
cohort, the first course consisted of either daunorubicin 60 mg/m² or idarubicin 12 mg/m² for 
3 days and cytarabine 100-200 mg/m² as a continuous infusion for 7 days (“7+3” regimen). 
Thereafter all patients received either one additional course of the same “7+3” regimen (N=4) 
or one course of a high-dose cytarabine (HD-AraC) (3000 mg/m²) regimen (N=109). All 
patients aged ≥60 years (N=19) were treated with a single course of “7+3” induction therapy. 
In case of more than 5% residual leukemic blasts in the bone marrow on day +16, induction 
was followed by either one additional course of the same regimen (N=5) one course of a HD-
AraC (1000 mg/m2) regimen (N=14). Depending on the scheduling of alloSCT, e.g. 
availability of an HLA-compatible donor, one (N=78) or two (N=7) additional courses HD-
AraC (3000 mg/m2 for patients aged <60 years or 1000 mg/m2 for patients aged ≥60 years) 
consolidation were given as early as 2 to 4 weeks after achievement of CR. In all patients, 
remission status was assessed at day +16 and day +28 after begin of induction therapy by 
conventional cytology, multicolor flow-cytometry, and histology. ER was defined as a 
marrow blast count below 5% at day +16 and DR was defined as marrow blast count below 
5% after the second course of induction therapy. 
Two weeks before begin of conditioning CR1 was confirmed by bone marrow analysis. As 
described previously, standard MAC consisted of 6 x 2 Gy total body irradiation (TBI) and 2 
x 60 mg/kg cyclophosphamide (14, 15). Patients with an HLA-mismatch received 3 x 10 
mg/kg anti-thymocyte globulin (ATG) (Fresenius). Patients with contraindications against 
MAC, i.e. age >55 years, a history of proven or probable invasive fungal infection, previous 
severe non-fungal infections, or impaired cardiac, renal, or pulmonary function, were treated 
with RIC, which consisted of 6 x 30 mg/m2 fludarabine, 2 x 4 mg/kg oral busulfan, and 4 x 10 
mg/kg ATG (Fresenius) (14, 15). Transplants were from related (n = 60) or unrelated (n = 72) 
donors and were HLA-matched (10/10 antigens) (n = 119) or HLA-mismatched (n = 13) 
according to high-resolution molecular typing.  
Prophylaxis of graft-versus-host disease and supportive care 
Prophylaxis of graft-versus-host disease (GvHD) consisted of either cyclosporine A and short 
course methotrexate for MAC patients or CSA and mycophenolate mofetil for RIC patients as 
described in detail previously (14). Acute GvHD (aGvHD) and chronic GvHD (cGvHD) were 
graded according to standard criteria (16). Whereas patients with aGvHD °I received topical 
treatment only, therapy of aGvHD °II-IV consisted of prednisolone (starting dose: 2 mg/kg) 
for 7 days, which was then gradually tapered according to the individual response. All 
patients received prophylactic ciprofloxacin, amphotericin B suspension, and aciclovir until 
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neutrophil counts reached 1 x 109/l. In patients with a platelet count of ≥50 x 109/l 
prophylactic cotrimoxazole was started at day +28 following alloSCT. Polyvalent 
immunoglobulins were administered bi-weekly until day +90 in patients with a total IgG 
below 5 g/l (14). 
Statistical analyses 
Statistical analyses were performed using NCSS 2007 (NCSS; Kayville, UT, USA) and SPSS 
14 (SPSS; Chicago, IL, USA) as of September 30th, 2013. Fisher’s exact test and χ2 test were 
used for comparing categorical data. Survival data (OS and DFS) were calculated according 
to Kaplan-Meier and tested univariately by log-rank test. Statistical significance was assessed 
at the p<0.05 level (two-sided). NRM and relapse are given as cumulative incidences 
calculated in a competing-risks setting (17). Cox proportional hazard regression model was 
used for univariate and multivariate analyses and included the following variables: AML 
subtype, age group, era of alloSCT, interval from diagnosis to alloSCT, extramedullary 
disease, Karnofsky performance status (KPS), type of conditioning, donor type/HLA-match, 
and stem cell source. First, a univariate model was calculated for all parameters. Thereafter, 
forward and backward selection (inclusion p=0.05, exclusion p=0.10) was applied. By 
definition, the lowest risk category within a group was assigned a hazard ratio (HR) of 1 and 
used as a reference. HRs are given with a 95% confidence interval (CI) and corresponding p-
values are shown. 
 
 
Results 
Overall outcome 
After a median follow-up of 56 (4-220) months for the surviving patients, 87 patients (66%) 
are alive and in CR. A relapse occurred in 26 patients (20%) after a median interval of 8 (1-
133) months, whereas 19 patients (14%) died from NRM. 47 patients (36%) had no aGvHD, 
whereas 27 (20%) or 58 patients (44%) developed °I or °II-IV aGvHD. Chronic GvHD was 
absent in 65 patients (49%) and limited or extensive chronic cGvHD occurred in 40 (30%) or 
27 patients (21%). Projected OS (95% CI) or DFS (95% CI) of the entire cohort after 1, 3, 5, 
and 10 years was 81% (74-88%), 68% (59-75%), 65% (56-74%), and 61% (49-73%) or 75% 
(67-83%), 68% (59-76%), 65% (56-74%), and 59% (47-71%). At the same time points the 
cumulative incidence of relapse (CI-R) (95% CI) or non-relapse mortality (CI-NRM) (95% 
CI) was 12% (8-20%), 19% (13-28%), 22% (15-32%), and 22% (15-32%) or 13% (8-20%), 
13% (8-20%), 13% (8-20%), and 17% (10-31%). 
Outcome according to remission status after the first course of induction therapy 
We next analyzed OS, DFS, CI-R, and CI-NRM according to the remission status after the 
first course of induction therapy. Specifically, 79 patients (60%) achieved ER defined as bone 
marrow blast <5% at day +16 after the first course of induction therapy, whereas 53 patients 
(40%) had a DR, i.e. first hematologic remission was achieved after two cycles of induction 
therapy. As shown in Table 1, there were no statistically significant differences with regards 
to gender, age group, AML subtype, transplant era, extramedullary disease, time from 
diagnosis to transplantation, KPS, donor type/HLA-match, conditioning regimen, or stem cell 
source between the ER and the DR subgroup. As displayed in Figure 1, patients who 
achieved ER had a significantly higher OS as compared to patients displaying DR (p=0.0313). 
Likewise, ER predicted a significantly lower relapse incidence CI-R (p=0.004). No 
statistically significant differences in CI-NRM between the two subgroups were found 
(p=0.638). 
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Uni- and multivariate analysis 
To further analyze the prognostic impact of ER versus DR we performed univariate analyses 
by using the Cox proportional hazard regression model. In addition to remission status, a 
number of other factors were analyzed in parallel. As shown in Table 2, DR was associated 
with an inferior OS and DFS as well as an increased relapse rate. Similarly, a KPS of ≤80% 
was predictive of a lower OS and DFS. Specifically, patients with a KPS of ≤80% had a 
higher risk of relapse, whereas the CI-NRM was not elevated as compared to patients with a 
KPS >80%. Patients transplanted from a mismatched unrelated donor (mMUD) had an 
inferior OS and DFS as compared to patients with a matched related or unrelated donor. 
Furthermore, patients with AML evolving from MPN or MDS as well as patients with 
therapy-related AML (tAML) had an inferior survival as compared to patients with de novo 
AML. All other factors examined were not predictive for OS, DFS, CI-R, or CI-NRM. 
Next, multivariate analysis was performed. As shown in Table 3, DR was associated with a 
significantly lower DFS and a higher CI-R. A KPS of ≤80% was an independent 
prognosticator for a lower OS. None of the factors examined was predictive for NRM (data 
not shown). 
Outcome according to type of conditioning 
Finally, we analyzed whether the type of conditioning therapy impacts on overall outcome 
and relapse incidence in patients achieving ER as compared to patients displaying DR (Table 
4). Neither in the ER nor in the DR subgroup a statistically significant difference in OS, DFS, 
or CI-R between patients treated with MAC or RIC was found. In particular, relapse risk was 
not elevated in patients displaying DR undergoing RIC-alloSCT. 
 
 
Discussion 
The analysis of 132 consecutive patients with AML and an intermediate cytogenetic risk 
profile who underwent alloSCT in CR1 at our center suggests, that achieving ER as compared 
to DR is associated with a favorable overall outcome. Importantly, we demonstrate that the 
beneficial effect of ER versus DR with regards to DFS and relapse incidence is maintained in 
multivariate analysis, which suggests that it has independent prognostic value. Furthermore, 
achieving ER strongly correlates with early blast clearance, which was shown before to be 
predictive for overall outcome of patients with AML irrespective of the type of post-remission 
therapy (8-11). In general, our data underline the importance of treatment response for 
generating an integrated risk-profile which, therefore, should be incorporated into a decision 
algorithm for patients with AML as has been proposed recently by the European Leukemia 
Network (3). Furthermore, our data implicate that the adverse effect of failure to achieve ER 
is not fully overcome by alloSCT even in patients entering CR after a consecutive course of 
induction therapy. A recent analysis reported by the ECOG suggests that patients entering 
remission after one or two cycles of induction have a similar prognosis (18). However, this 
cohort was heterogeneous with respect to cytogenetic risk group and type of post-remission 
therapy, i.e. transplant versus conventional therapy, which may explain the discrepancy. 
Patients reaching ER are characterized by a remarkably low relapse incidence, which is in the 
range of 10-15% at 10 years after alloSCT. Likewise, NRM levels off around 10-15% as early 
as 18 months post-transplant and remains stable thereafter. In principle, these results 
underline that alloSCT is not only feasible in this setting, but highly effective and safe. 
Consequently, alloSCT should be considered as first choice post-remission treatment option 
Hemmati et al.  Impact of early remission in AML undergoing alloSCT in CR1 
 6 
for medically fit patients with intermediate-risk AML entering CR1 if an HLA-compatible 
donor is available. In this regard, our results are in line with a number of recently published 
studies reporting data from donor-versus-no donor comparisons, matched pair analyses, and 
randomized phase-III multicenter clinical trials (3, 19-22). Nonetheless, it might be of interest 
to address whether the speed of achieving remission, i.e. ER versus DR, is of prognostic 
relevance in other genetic risk groups of AML patients undergoing alloSCT in CR1 as well. 
In contrast, both OS and DFS are significantly reduced in patients showing DR albeit CR1 
was reached after a second induction cycle is administered. This is due to a considerably 
higher relapse incidence reaching a plateau of close to 40% at five years after alloSCT. It is 
obvious to assume that occult populations of leukemic cells outlasting two or more courses of 
induction/consolidation therapy are the primary source of disease recurrence in this situation. 
Indeed, two recently published analyses using pre-transplant minimal residual disease (MRD) 
monitoring suggest that even minute populations of residual leukemic cells, e.g. below <0.1% 
as detected by multicolor flow-cytometry, in patients achieving morphologic CR prior to 
alloSCT give rise to relapse and, thereby, have a tremendous impact on overall outcome (23, 
24). Specifically, 3-year OS declines to around 30% in MRD-positive patients as compared to 
75% in patients MRD-negative pre-transplant. In our cohort, data pre-transplant MRD were 
available in only 53/132 patients. In the subgroup of MRD-negative patients (N=33) 4 
relapses occurred, whereas in 8/20 MRD-positive patients relapsed after alloSCT (p=0.007). 
However, due to the limited number of patients in each subgroup we are unable to interpret 
pre-transplant MRD in the context of ER versus DR. Nonetheless, this inevitably brings up 
the question how to tackle the dilemma of failure to achieve an early and/or molecular CR 
before proceeding to alloSCT. One approach could be to apply repetitive courses of 
consolidation chemotherapy until MRD negativity is reached. A recently published analysis 
of EBMT registry data clearly indicates that, at least for patients with AML undergoing RIC-
alloSCT in CR1, consolidation therapy neither reduces the risk of relapse, nor improves 
overall outcome (25). One should assume that the results in patients undergoing alloSCT 
following MAC are similar. Alternatively, risk-adapted post-transplant management, e.g. 
early cessation of immunosuppressive therapy and/or the use adoptive immunotherapy to 
fully exploit the beneficial graft-versus-leukemia (GvL) effect might serve to overcome the 
risk of therapeutic failure in this situation (26-28). This strategy is supported by the 
observation that the occurrence of GvHD reduces the risk of disease recurrence irrespective of 
the presence or absence or MRD (24). Furthermore, novel therapeutics such as 
hypomethylating agents might be used to prevent relapse by enhancing the GvL effect (29, 
30). In any event, despite the higher relapse risk in patients who, in addition of being in 
hematologic remission, do not meet more stringent response criteria, e.g. MRD negativity, 
after two courses of induction chemotherapy, alloSCT should not be withheld, because the 
results with conventional post-remission therapy is dismal.  
In patients showing delayed remission during induction therapy, intensive conditioning such 
as a myeloablative approach might be compensatory by effectively eradicating residual 
leukemic cells in the recipient prior to allografting. Therefore, we analyzed overall outcome 
and relapse incidence according to the type of conditioning in both the ER and the DR 
subgroup. However, we failed to reveal any significant differences between patients treated 
with either MAC or RIC prior to alloSCT. Specifically, OS and relapse incidence were not 
lowered by MAC as compared to RIC in the DR group. Yet, the number of patients in each 
subgroup is small and, therefore, data must be interpreted with due caution. Analyzing larger 
data sets should allow for answering this important question. 
Despite the limitations of a retrospective analysis in a rather small cohort of patients, our data 
indicate that achieving early remission by induction therapy is an independent predictor for 
overall outcome in patients with AML and an intermediate risk karyotype transplanted in 
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CR1. In turn, delayed remission is associated with an adverse outcome and, therefore, should 
prompt for maneuvers to counteract the high risk of disease recurrence. In addition to 
transplantion-specific options, e.g. rapid tapering of immunosuppression and the 
administration of donor lymphocyte infusions (DLI), these may also include the use of novel 
therapeutics including hypomethylating agents or, when applicable, mulitkinase inhibitors, 
e.g. in FLT3-ITD positive AML, in the post-transplant setting (31, 32). Furthermore, 
innovative strategies to detect and treat an impeding relapse after transplant as early as 
possible are clearly warranted in the future.  
 
 
Acknowledgements 
We thank Sabine Diehl and Doreen Uhlenbroch for excellent data management as well as the 
nursing team for delivering superb patient care. 
 
 
 
Conflict of interest 
The authors declare no conflict of interest.  
Hemmati et al.  Impact of early remission in AML undergoing alloSCT in CR1 
 8 
References 
1. Miller CA, Wilson RK, Ley TJ. Genomic landscapes and clonality of de novo AML. N Engl J 
Med. 2013; 369(15): 1473. 
2. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet. 2013; 381(9865): 484-95. 
3. Cornelissen JJ, Gratwohl A, Schlenk RF, Sierra J, Bornhäuser M, Juliusson G, Racil Z, Rowe JM, 
Russell N, Mohty M, Löwenberg B, Socie G, Niederwieser D, Ossenkoppele GJ. The European 
LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with 
AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol. 2012; 9(10): 579-
90. 
4. Estey EH. How to manage high-risk acute myeloid leukemia. Leukemia. 2012; 26(5): 861-9. 
5. Büchner T, Urbanitz D, Hiddemann W, Rühl H, Ludwig WD, Fischer J, Aul HC, Vaupel HA, 
Kuse R, Zeile G, et al. Intensified induction and consolidation with or without maintenance 
chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML 
Cooperative Group. J Clin Oncol. 1985; 3(12): 1583-9. 
6. Estey EH, Shen Y, Thall PF. Effect of time to complete remission on subsequent survival and 
disease-free survival time in AML, RAEB-t, and RAEB. Blood. 2000; 95(1): 72-7. 
7. Preisler HD, Priore R, Azarnia N, Barcos M, Raza A, Rakowski I, Vogler R, Winton EL, 
Browman G, Goldberg J, et al. Prediction of response of patients with acute nonlymphocytic 
leukaemia to remission induction therapy: use of clinical measurements. Br J Haematol. 1986; 
63(4): 625-36. 
8. Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, Fonatsch C, 
Haase D, Schoch C, Hossfeld D, Lengfelder E, Aul C, Heyll A, Maschmeyer G, Ludwig WD, 
Sauerland MC, Heinecke A. Double induction strategy for acute myeloid leukemia: the effect of 
high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin 
and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999; 
93(12): 4116-24. 
9. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, Harrison CJ, Rees JK, Stevens RF, 
Walker H. A simple, robust, validated and highly predictive index for the determination of risk-
directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United 
Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J 
Haematol. 1999; 107(1): 69-79. 
10. Kern W, Voskova D, Schoch C, Schnittger S, Hiddemann W, Haferlach T. Prognostic impact of 
early response to induction therapy as assessed by multiparameter flow cytometry in acute 
myeloid leukemia. Haematologica. 2004; 89(5): 528-40. 
11. Kern W, Haferlach T, Schoch C, Löffler H, Gassmann W, Heinecke A, Sauerland MC, Berdel W, 
Büchner T, Hiddemann W. Early blast clearance by remission induction therapy is a major 
independent prognostic factor for both achievement of complete remission and long-term 
outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 
1992 Trial. Blood. 2003; 101(1): 64-70. 
12. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, 
Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR. Karyotypic analysis predicts 
outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest 
Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000; 96(13): 4075-83. 
13. Büchner T, Schlenk RF, Schaich M, Döhner K, Krahl R, Krauter J, Heil G, Krug U, Sauerland 
MC, Heinecke A, Spath D, Kramer M, Scholl S, Berdel WE, Hiddemann W, Hoelzer D, 
Hehlmann R, Hasford J, Hoffmann VS, Döhner H, Ehninger G, Ganser A, Niederwieser DW, 
Pfirrmann M. Acute Myeloid Leukemia (AML): different treatment strategies versus a common 
Hemmati et al.  Impact of early remission in AML undergoing alloSCT in CR1 
 9 
standard arm--combined prospective analysis by the German AML Intergroup. J Clin Oncol. 
2012; 30(29): 3604-10. 
14. Hemmati PG, Terwey TH, Massenkeil G, le Coutre P, Vuong LG, Neuburger S, Dörken B, 
Arnold R. Reduced intensity conditioning prior to allogeneic stem cell transplantation in first 
complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk 
karyotype. Int J Hematol. 2010; 91(3): 436-45. 
15. Terwey TH, Vega-Ruiz A, Hemmati PG, Martus P, Dietz E, le Coutre P, Massenkeil G, Dörken 
B, Arnold R. NIH-defined graft-versus-host disease after reduced intensity or myeloablative 
conditioning in patients with acute myeloid leukemia. Leukemia. 2012; 26(3): 536-42. 
16. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, 
Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, 
Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, 
Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus 
development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis 
and staging working group report. Biol Blood Marrow Transplant. 2005; 11(12): 945-56. 
17. Hemmati PG, Terwey TH, le Coutre P, Vuong LG, Massenkeil G, Dörken B, Arnold R. A 
modified EBMT risk score predicts the outcome of patients with acute myeloid leukemia 
receiving allogeneic stem cell transplants. Eur J Haematol. 2011; 86(4): 305-16. 
18. Rowe JM, Kim HT, Cassileth PA, Lazarus HM, Litzow MR, Wiernik PH, Tallman MS. Adult 
patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of 
induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by 
the Eastern Cooperative Oncology Group. Cancer. 2010; 116(21): 5012-21. 
19. Nagler A, Rocha V, Labopin M, Unal A, Ben Othman T, Campos A, Volin L, Poire X, Aljurf M, 
Masszi T, Socie G, Sengelov H, Michallet M, Passweg J, Veelken H, Yakoub-Agha I, Shimoni A, 
Mohty M. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in 
remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body 
irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of 
the European group for blood and marrow transplantation. J Clin Oncol. 2013; 31(28): 3549-56. 
20. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, Djulbegovic BJ, Wadleigh M, DeAngelo 
DJ, Stone RM, Sakamaki H, Appelbaum FR, Döhner H, Antin JH, Soiffer RJ, Cutler C. 
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: 
systematic review and meta-analysis of prospective clinical trials. Jama. 2009; 301(22): 2349-61. 
21. Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, 
Beverloo HB, van Marwijk Kooy M, Wijermans PW, Biemond BJ, Vellenga E, Verdonck LF, 
Ossenkoppele GJ, Löwenberg B. Comparative analysis of the value of allogeneic hematopoietic 
stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other 
cytogenetic risk categories. J Clin Oncol. 2012; 30(17): 2140-6. 
22. Stelljes M, Krug U, Beelen DW, Braess J, Sauerland MC, Heinecke A, Ligges S, Sauer T, 
Tschanter P, Thoennissen GB, Berning B, Kolb HJ, Reichle A, Holler E, Schwerdtfeger R, 
Arnold R, Scheid C, Muller-Tidow C, Woermann BJ, Hiddemann W, Berdel WE, Buchner T. 
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid 
leukemia: a prospective matched pairs analysis. J Clin Oncol. 2014; 32(4): 288-96. 
23. Walter RB, Gooley TA, Wood BL, Milano F, Fang M, Sorror ML, Estey EH, Salter AI, Lansverk 
E, Chien JW, Gopal AK, Appelbaum FR, Pagel JM. Impact of pretransplantation minimal 
residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative 
hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011; 29(9): 1190-7. 
24. Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, 
Delaney C, Radich JP, Estey EH, Appelbaum FR. Significance of minimal residual disease before 
myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete 
remission. Blood. 2013; 122(10): 1813-21. 
Hemmati et al.  Impact of early remission in AML undergoing alloSCT in CR1 
 10 
25. Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, 
Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, 
Bunjes D, Arnold R, Nagler A, Mohty M. Impact of postremission consolidation chemotherapy 
on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients 
with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia 
Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014; 
120(6): 855-63. 
26. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, 
Blaise D, Janssen JJ, Petersen E, Socie G, Nagler A, Rocha V, Mohty M. Impact of graft-versus-
host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute 
myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for 
blood and marrow transplantation. Leukemia. 2012; 26(12): 2462-8. 
27. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, Frassoni F, Boiron JM, Yin 
JL, Finke J, Shouten H, Blaise D, Falda M, Fauser AA, Esteve J, Polge E, Slavin S, Niederwieser 
D, Nagler A, Rocha V. Comparative outcome of reduced intensity and myeloablative 
conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation 
for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey 
from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow 
Transplantation (EBMT). Leukemia. 2005; 19(12): 2304-12. 
28. Valcarcel D, Martino R, Caballero D, Martin J, Ferra C, Nieto JB, Sampol A, Bernal MT, Pinana 
JL, Vazquez L, Ribera JM, Besalduch J, Moraleda JM, Carrera D, Brunet MS, Perez-Simon JA, 
Sierra J. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome 
after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-
versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008; 26(4): 577-84. 
29. Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF. In 
vivo administration of hypomethylating agents mitigate graft-versus-host disease without 
sacrificing graft-versus-leukemia. Blood. 2010; 116(1): 129-39. 
30. Jabbour E, Giralt S, Kantarjian H, Garcia-Manero G, Jagasia M, Kebriaei P, de Padua L, Shpall 
EJ, Champlin R, de Lima M. Low-dose azacitidine after allogeneic stem cell transplantation for 
acute leukemia. Cancer. 2009; 115(9): 1899-905. 
31. Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, 
Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer RG, Brugger W, Vohringer 
M, Dreger P, Mori M, Basara N, Schäfer-Eckart K, Schultheis B, Baldus C, Neubauer A, 
Burchert A. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes 
with allo-immune effects to induce sustained responses. Leukemia. 2012; 26(11): 2353-9. 
32. Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, 
Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G. Azacitidine 
and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after 
allogeneic stem cell transplantation. Leukemia. 2013; 27(6): 1229-35. 
 
 
Hemmati et al.  Impact of early remission in AML undergoing alloSCT in CR1 
 11 
 
 
Early remission 
Number (%) 
N=79 
Delayed remission 
Number (%) 
N=53 
P 
Gender 
   Male 
   Female 
 
36 (46) 
43 (54) 
 
23 (43) 
30 (57) 
0.81 
Median age, years (range) 48 (17-70) 47 (19-70) 0.78 
Age group 
   <40 years 
   40-60 years 
   >60 years 
 
29 (37) 
33 (42) 
17 (21) 
 
14 (26) 
30 (57) 
9 (17) 
0.24 
AML subtype 
   De novo AML 
   Other  
 
60 (76) 
19 (24) 
 
39 (74) 
14 (26) 
0.76 
Year of alloSCT 
   1994 – 2004 
   2005 – 2010 
   2011 – 2013 
 
19 (24) 
37 (47) 
23 (29) 
 
16 (30) 
15 (28) 
22 (42) 
0.10 
Extramedullary disease 
   Absent 
   Present 
 
70 (89) 
9 (11) 
 
49 (92) 
4 (8) 
0.47 
Induction/consolidation courses 
applied before alloSCT* 
   2 
   3 
   >3 
 
 
31 (39) 
44 (56) 
4 (5) 
 
 
16 (30) 
34 (64) 
3 (6) 
0.57 
Early blast clearance 
   Yes 
   No 
 
76 (96) 
3 (4) 
 
2 (4) 
51 (96) 
<0.001 
Interval from diagnosis to SCT 
   < 6 months 
   ≥ 6 months 
 
37 (47) 
42 (53) 
 
29 (55) 
24 (45) 
0.37 
 
Karnofsky Performance Status 
   100 – 90% 
   ≤ 80% 
 
70 (89) 
9 (11) 
 
45 (85) 
8 (15) 
0.53 
 
Donor type 
   MRD 
   MUD 
   mMUD 
 
35 (44) 
36 (46) 
8 (10) 
 
25 (47) 
23 (43) 
5 (10) 
0.95 
Type of conditioning 
   MAC 
   RIC 
 
37 (47) 
42 (53) 
 
21 (40) 
32 (60) 
0.41 
 
Stem cell source 
   Bone marrow 
   Peripheral blood stem cells 
 
8 (10) 
71 (90) 
 
7 (13) 
46 (87) 
0.58 
Donor Lymphocyte Infusion 
   No 
   Yes 
 
71 (90) 
8 (11) 
 
45 (85) 
8 (15) 
0.39 
 
Table 1: Patients and treatment characteristics. 
The entire cohort (N=132) was subdivided in patients who achieved early blast clearance (ER) (N=79) or 
delayed blast clearance (DR) (N=53). Abbreviations: alloSCT: allogeneic stem cell transplantation, AML: acute 
myeloid leukemia, MAC: myeloablative conditioning, RIC: reduced intensity conditioning, MRD: matched 
related donor, MUD: matched unrelated donor, mMUD: mismatched unrelated donor. * All patients received at 
least one course of high-dose cytarabine (HD-AraC), i.e. either during induction or consolidation therapy. 
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Table 2: Univariate analysis. 
Univariate analyses were performed using the Cox proportional hazard regression model. Hazard ratios (HR) 
with the 95% CI are given along with P-values for the comparison of the respective category with the first one. 
Variables with significant differences are bold-faced.  
 
No. of 
patients 
(%) 
OS 
HR (95% CI) P 
DFS 
HR (95% CI) P 
Relapse 
HR (95% CI) P 
NRM 
HR (95% CI) P 
Age group 
   <40 years 
   40-60 years 
   >60 years 
 
43 (33) 
63 (48) 
26 (19) 
 
1.0 
1.21 (0.60-2.46) 
1.63 (0.69-3.88) 
 
 
0.592 
0.271 
 
1.0 
1.23 (0.61-2.50) 
1.58 (0.66-3.75) 
 
 
0.561 
0.301 
 
1.0 
1.26 (0.51-3.11) 
1.52 (0.49-4.72) 
 
 
0.616 
0.473 
 
1.0 
1.20 (0.39-3.71) 
1.67 (0.44-6.40) 
 
 
0.751 
0.451 
AML subtype 
   De novo AML 
   Other  
 
99 (75) 
33 (25) 
 
1.0 
1.97 (1.03-3.76) 
 
 
0.040 
 
1.0 
1.68 (0.87-3.24) 
 
 
0.124 
 
1.0 
1.57 (0.65-3.79) 
 
 
0.315 
 
1.0 
1.83 (0.68-4.96) 
 
0.233 
 
Year of alloSCT 
   1994 – 2004 
   2005 – 2010 
   2011 – 2013 
 
35 (27) 
52 (39) 
45 (34) 
 
1.0 
1.20 (0.57-2.55) 
1.53 (0.64-3.68) 
 
 
0.634 
0.333 
 
1.0 
1.33 (0.62-2.87) 
1.21 (0.50-2.91) 
 
 
0.461 
0.670 
 
1.0 
1.88 (0.67-5.27) 
1.66 (0.49-5.65) 
 
 
0.232 
0.421 
 
1.0 
0.81 (0.25-2.64) 
0.82 (0.24-2.83) 
 
 
0.720 
0.752 
Extramedullary disease 
   Absent 
   Present 
 
119 (90) 
13 (10) 
 
1.0 
0.62 (0.19-2.03) 
 
 
0.436 
 
1.0 
0.44 (0.11-1.83) 
 
 
0.259 
 
1.0 
1.03 (0.64-3.39) 
 
 
0.992 
 
1.0 
1.29 (0.30-5.66) 
 
0.733 
 
Remission 
   Early remission (ER) 
   Delayed remission (DR) 
 
79 (60) 
53 (40) 
 
1.0 
1.92 (1.05-3.53) 
 
 
0.035 
 
1.0 
1.89 (1.03-3.47) 
 
 
0.040 
 
1.0 
3.32 (1.46-7.55) 
 
 
0.004 
 
1.0 
0.83 (0.31-2.26) 
 
 
0.721 
Intervall from diagnosis to 
SCT 
   < 6 months 
   ≥ 6 months 
 
66 (50) 
66 (50) 
 
1.0 
0.75 (0.41-1.39) 
 
 
0.360 
 
1.0 
0.76 (0.41-1.40) 
 
 
0.381 
 
1.0 
0.70 (0.32-1.55) 
 
 
0.381 
 
1.0 
0.85 (0.33-2.21) 
 
 
0.745 
Karnofsky Performance Status 
   100 – 90% 
   ≤ 80% 
 
115 (87) 
17 (13) 
 
1.0 
2.14 (1.02-4.48) 
 
 
0.042 
 
1.0 
2.26 (1.08-4.74) 
 
 
0.031 
 
1.0 
2.84 (1.13-7.11) 
 
 
0.027 
 
1.0 
1.59 (0.46-5.56) 
 
 
0.467 
Donor type 
   MRD 
   MUD 
   mMUD 
 
60 (45) 
59 (45)  
13 (10) 
 
1.0 
1.12 (0.58-2.19) 
2.58 (1.07-6.29) 
 
 
0.730 
0.035 
 
1.0 
1.21 (0.62-2.35) 
2.75 (1.13-6.68) 
 
 
0.579 
0.026 
 
1.0 
0.88 (0.37-2.10) 
2.34 (0.75-7.33) 
 
 
0.774 
0.143 
 
1.0 
1.97 (0.66-5.94) 
3.75 (0.88-16.0) 
 
 
0.227 
0.074 
Type of conditioning 
   MAC 
   RIC 
 
59 (45) 
74 (55) 
 
1.0 
1.20 (0.65-2.22) 
 
 
0.559 
 
1.0 
1.19 (0.64-2.20) 
 
 
0.583 
 
1.0 
0.95 (0.43-2.10) 
 
 
0.890 
 
1.0 
1.70 (0.62-4.69) 
 
 
0.302 
Stem cell source 
   Bone marrow 
   Peripheral blood stem cells 
 
15 (11) 
117 (89) 
 
1.0 
0.73 (0.33-1.62) 
 
 
0.449 
 
1.0 
0.68 (0.31-1.50) 
 
 
0.337 
 
1.0 
0.51 (0.20-1.31) 
 
 
0.161 
 
1.0 
1.20 (0.26-5.49) 
 
 
0.813 
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No. of 
patients 
(%) 
OS 
HR (95% CI) P 
DFS 
HR (95% CI) P 
Relapse 
HR (95% CI) P 
Remission 
   Early remission (ER) 
   Delayed remission (DR) 
 
79 (59) 
53 (41) 
   
1.0 
3.37 (1.50-7.61) 
 
 
0.002 
 
1.0 
3.55 (1.61-7.94) 
 
 
0.002 
Karnofsky Performance Status 
   100-90% 
   ≤ 80% 
 
115 (87) 
17 (13) 
 
1.0 
2.58 (1.31-5.12) 
 
 
0.007 
    
 
Table 3: Multivariate Analysis. 
Prognostic variables examined were age group, acute myeloid leukemia (AML) subtype, transplant era, 
extramedullary disease, blast clearance, interval from diagnosis to transplantation, Karnofsky-Performance 
Status, donor type and match, type of conditioning, and stem cell source. The P-values refer to the comparison of 
the respective category with the first one. Bold-faced text indicates parameters showing statistically significant 
differences.  
 
 
 
 
 
 
 
No. of 
patients 
(%) 
OS 
HR (95% CI) P 
DFS 
HR (95% CI) P 
Relapse 
HR (95% CI) P 
Early remission 
   MAC 
   RIC  
 
38 (48) 
41 (52) 
 
1.0 
0.85 (0.35-2.07) 
 
 
0.727 
 
1.0 
0.84 (0.34-2,04) 
 
 
0.700 
 
1.0 
0.60 (0.14-2.42) 
 
 
0.468 
Delayed remission 
   MAC 
   RIC  
 
21 (41) 
32 (59) 
 
1.0 
1.51 (0.62-3.66) 
 
 
0.366 
 
1.0 
1.53 (0.63-373) 
 
 
0.346 
 
1.0 
1.07 (040-2.89) 
 
 
0.897 
 
Table 4: Outcome according to type of conditioning in ER versus DR patients. 
Univariate analysis was performed by using the Cox proportional hazard regression model in the ER and the DR 
subgroup of patients treated with either RIC or MAC prior to alloSCT.  
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Figure 1: Outcome of alloSCT in patients achieving early remission (ER) versus delayed remission (DR).  
Overall survival (OS), cumulative incidence of relapse (CI-R) and non-relapse mortality (CI-NRM) were 
analyzed by Kaplan-Meier (OS) or calculated in a competing risk setting (CI-R, CI-NRM). In patients achieving 
early remission (ER) OS and CI-R is significantly better as compared to patients with delayed remission (DR), 
whereas no significant difference in NRM between the subgroups was found.  
